Now streaming on COVID-19 pandemic has affected the global illicit drug industry. According to a new report, Chinese crime syndicates are now thriving because of various sociopolitical factors in 2020. Incidentally, America's war on drugs will soon become even more difficult to manage.
The Business of Drugs doesn't ignore Netflix docies and senses blatant deception.
A May 2020 report by The Business of Drugs reveal that compares Myanmar "yaba" production to McDonald's yearly output of hamburgers. Counternarcotics officials are also concerned about the mass distribution of methyl fentanyl, which suggests that Myanmar is becoming a major player in the worldwide business of drugs.
In The Business of Drugs, Fox suspects the anti-drug campaign she witnesses in Myanmar is a "dog and pony show" that the influential figures are using to deflect public attention from the truth. Drug hauls looks good on camera for government agencies, but the fact remains that a single Myanmar meth lab can produce 10,000 pills per hour, according to Fox's Netflix docies. In Southeast Asia, drug production and distribution continue to thrive because of existing social conditions and the wider accessibility of meth and fentanyl, certainly during the COVID-19 pandemic. The current problem was recently summed up by Jeremy Douglas, the regional representative for the United Nations Office on Drugs and Crime in Southeast Asia:
“Organized crime and drug syndicates look for business environments where there’s government dysfunction or limited government control, as well as easy access to the chemicals... Shan State hits every mark.”
As for the bigger picture, Douglas believes that the mass production of meth and fentanyl in Myanmar will ultimately translate to the business of drugs in Mexico and America. In fact, it could make the inherent violence of the underworld drug trade even more chaotic and complex if Asian dealers "move in" on their Western counterparts. Douglas states that this new conflict could become "a direct threat to our public health," which will undoubtedly be addressed in the the next installment of The Business of Drugs.